Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 2/20 | 0.50 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.44 |
| ▸ | KRAS | P01116 | 3/20 | 0.43 |
| ▸ | VNN1 | O95497 | 2/20 | 0.36 |
| ▸ | BTK | Q06187 | 6/20 | 0.35 |
| ▸ | JAK3 | P52333 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31395068 | 1.00 | PDK1 (0.50) | PDK1GLRA1KRASVNN1BTK | |
| SCHEMBL21641656 | 1.00 | PDK1 (0.50) | PDK1GLRA1KRASVNN1BTK | |
| SCHEMBL6043841 | 0.84 | PDK1 (0.51) | PDK1GLRA1KRASVNN1NPC1 | |
| SCHEMBL28338015 | 0.81 | PDK1 (0.49) | PDK1GLRA1KRASVNN1JAK3 | |
| SCHEMBL8034011 | 0.78 | PDK1 (0.53) | PDK1GLRA1VNN1NPC1ALDH1A1 | |
| SCHEMBL20839803 | 0.77 | PDK1 (0.57) | PDK1KRASBTKJAK3 | |
| SCHEMBL9700171 | 0.77 | SMN1; SMN2 (0.46) | PDK1NPC1ALDH1A1NPSR1 | |
| SCHEMBL18125963 | 0.77 | PDK1 (0.56) | PDK1GLRA1VNN1NPC1ALDH1A1 | |
| SCHEMBL3991342 | 0.77 | PDK1 (0.56) | PDK1GLRA1VNN1NPC1ALDH1A1 | |
| SCHEMBL2933380 | 0.77 | PDK1 (0.56) | PDK1GLRA1VNN1NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011291-A1 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011291-A1 | KEAP1 INHIBITORS AND USES THEREOF | KEAP1, NFE2L2, NQO1 | PDK1 877/4885GLRA1 2807/4885KRAS 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.